Top View
- Treatment of Melanoma/Renal Cell Carcinoma
- A Retrospective Analysis of Dabrafenib And/Or Dabrafenib Plus
- Treatment of Melanoma and Breast Cancer
- BRAF, MEK and KIT Inhibitors for Melanoma: Adverse Events and Their Management
- NHS Borders NHS Borders Education Centre Planning & Performance Borders General Hospital Melrose Roxburghshire TD6 9BD 01896 825545 [email protected]
- New Frontiers in Therapy of Peripheral Nerve Sheath Tumors In
- Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma
- Carboplatin Yields Extended Survival in Advanced BRAF Wild-Type Melanoma: Results of a Clinical/Correlative Prospective Phase II Clinical Trial
- TAFINLAR and Trametinib, After One Month of Treatment, TAFINLAR Safely and Effectively
- 1 Title: the BRAF and MEK Inhibitors Dabrafenib and Trametinib
- Non-Small Cell Lung Cancer
- Dabrafenib and Trametinib
- Efficacy of Dabrafenib Plus Trametinib Combination in Patients
- DRUG NAME: Dabrafenib
- BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma LISA WALTER and LUCIE HEINZERLING
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Drug Updates Medina FINAL.Pptx
- Analysis of Treatment with Vemurafenib and Dabrafenib in Patients With
- Dual-Specificity Protein Phosphatase DUSP4 Regulates Response to MEK
- Consumption of Oral Anticancer Drugs in Norway Compared by Different
- Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
- Dabrafenib) Capsules, for Oral Use Serious Skin Toxicity: Monitor for Skin Toxicities
- Comparisons of Non-Small Cell Lung Cancer Treatment Options: New Zealand and Australia Versus European Society for Medical Oncology (ESMO) Guidelines
- Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination with MEK Inhibitors for Metastatic Melanoma
- Targeted Therapies in Melanoma
- Non-Small-Cell Lung Cancer?
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Combating Acquired Resistance to MAPK Inhibitors in Melanoma by Targeting Abl1/2-Mediated Reactivation of MEK/ERK/MYC Signaling
- February 2021
- 202806Orig1s000
- Combining Tkis in Melanoma
- Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia
- Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- FOI Reference: FOI 422 – 2021 Title: Research on the Treatment of Lung
- Tafinlar (Dabrafenib)
- Table of Contents (PDF)
- BRAF Testing for Melanoma Kinase Inhibitor Responses
- ATC/DDD Classification (Temporary)
- FOI 138 – 2122 Title: Incidence and Treatment of Melanoma and Renal Cell Carcinoma Date: June 2021 FOI Category: Pharmacy
- TAFINLAR in Combination TAFINLAR Safely and Effectively
- Oncofocus Patient Test Report
- Clinical Trials Appendix Q1 2019 Results Update
- CHMP Assessment Report for Tafinlar
- For Health Professionals Who Care for Cancer Patients
- NCCN Guidelines for Thyroid Carcinoma V.1.2018 – Web Teleconference on 10/13/17
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Package Leaflet: Information for the Patient Tafinlar® 50 Mg Hard
- Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
- Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines
- Australian Public Assessment Report for Dabrafenib Mesilate
- Current Development Status of MEK Inhibitors
- All ETCTN Trials
- Increased MAPK Reactivation in Early Resistance to Dabrafenib/Trametinib Combination Therapy of BRAF-Mutant Metastatic Melanoma
- Dabrafenib Trametinib Ver1
- Availability of Evidence of Benefits on Overall Survival and Quality of Life Of
- Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
- Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
- The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor
- The Study Listed May Include Approved and Non-Approved Uses, Formulations Or Treatment Regimens
- NF1 Clinical Pipeline: Active Interventional Drug Therapies
- HOPA News Volume 10, Issue 3, 2013
- BRAF, NRAS and C-KIT Advanced Melanoma
- Current Insights Into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
- Liste Der Oralen Antineoplastischen Wirkstoffe Stand: 29.06.2021
- Evaluation of Drug Therapy Costs for Patients with Breast Cancer, Melanoma and Renal Cell Carcinoma in Moscow in 2016-2017